Calcium's role in bone pain unclearIn-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution.
Most Relevant Research
We explored the impact of calcium treatment on bone pain in patients who developed osteomalacia, a condition linked to intravenous iron infusions. Our focus was on a group of 13 patients diagnosed with this condition, who experienced low phosphate levels due to excess fibroblast growth factor 23 (iFGF23) after receiving ferric carboxymaltose (FCM) infusions.
After halting the FCM infusions, these patients were given supportive treatment, which included phosphate, calcium, and active Vitamin D supplementation. We observed improvements in biochemical markers, including increased phosphate levels and reduced pain scores. However, it’s important to note that while calcium was part of the treatment regimen, we could not isolate its specific effects on bone pain from the other supportive measures used.
Ultimately, our findings highlight the importance of monitoring phosphate levels in patients receiving FCM, and stopping these infusions effectively addresses phosphate wasting. Although supportive treatment showed improvements in pain and bone density, the direct impact of calcium on bone pain remains unclear given the combination of treatments involved.